Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2015-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于全资子公司取得产品生产批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (558 characters) about a subsidiary obtaining a production permit for a pharmaceutical product. It includes a regulatory approval update from the National Medical Products Administration (国家食品药品监督管理总局) and a caution to investors. There is no financial data, no detailed report, no meeting or voting information, and no mention of financial results or management changes. The document is an official regulatory announcement about product approval, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2015-04-27 Chinese
关于全资子公司获批设立六个单采血浆站分站的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval for a wholly-owned subsidiary to establish six plasma collection sub-stations. It is a regulatory announcement about operational expansion and does not contain financial statements, audit information, or detailed financial data. The document is short (650 characters) and serves as an official notice to shareholders and the public about a business development. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it is not announcing the release of a report. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2015-04-24 Chinese
关于实际控制人协议受让股份过户完成的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the completion of a share transfer involving the company's actual controller and a major shareholder. It details the change in shareholding percentages and the completion of the share transfer registration. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. The content fits the description of a Major Shareholding Notification, as it informs about changes in significant share ownership levels.
2015-04-24 Chinese
2015年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 First Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial data and shareholder information. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year (the first quarter of 2015) confirms it is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2015
2015-04-22 Chinese
2014年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2014年度股东大会决议公告" which translates to "2014 Annual General Meeting Resolution Announcement." It details the convening of the shareholders' meeting, attendance, voting results on various proposals including the 2014 annual reports, financial statements, profit distribution, and amendments to company articles. It also includes legal opinions confirming the validity of the meeting and resolutions. The document is a formal announcement of the voting results and resolutions passed at the Annual General Meeting (AGM). It does not contain the full annual report or financial statements themselves but reports on the meeting outcomes and voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4866 characters, which is consistent with an announcement rather than a full report. Hence, the classification is DVA with high confidence.
2015-04-22 Chinese
2015年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015年第一季度报告正文" which translates to "2015 First Quarter Report". It contains detailed financial data for the quarter, including revenue, net profit, earnings per share, cash flow, and shareholder information. The document also includes management statements ensuring the accuracy of the report, explanations of financial changes, and forecasts for the next half-year period. The length of the document (13,779 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2015
2015-04-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.